Screener
Kiniksa Pharmaceuticals International, plc KNSA Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The source filing: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed July 28, 2026.
- Filed
- Jul 28, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-087545
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $175,677 | $165,596 |
| Short-term investments | 350,251 | 248,478 |
| Accounts receivable, net | 23,490 | 15,594 |
| Inventory | 70,930 | 54,895 |
| Prepaid expenses and other current assets | 48,285 | 42,614 |
| Total current assets | 668,633 | 527,177 |
| Property and equipment, net | 2,575 | 1,943 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Kiniksa Pharmaceuticals International, plc's accounts receivable?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported accounts receivable of $23.49M in Q2 2026.
- How has Kiniksa Pharmaceuticals International, plc's accounts receivable changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's accounts receivable decreased by 26.4% year-over-year, from $31.91M to $23.49M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's accounts receivable?
- Over 4 years (2021 to 2025), Kiniksa Pharmaceuticals International, plc's accounts receivable has grown at a 40.6% compound annual growth rate (CAGR), from $3.99M to $15.59M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.
Ask your AI about Kiniksa Pharmaceuticals International, plc's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude